203 related articles for article (PubMed ID: 33534224)
21. High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature.
Campione E; Di Prete M; Lozzi F; Lanna C; Spallone G; Mazzeo M; Cosio T; Rapanotti C; Dika E; Gaziano R; Orlandi A; Bianchi L
Chemotherapy; 2020; 65(1-2):2-10. PubMed ID: 32777789
[TBL] [Abstract][Full Text] [Related]
22. FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma.
Casey D; Demko S; Shord S; Zhao H; Chen H; He K; Putman A; Helms W; Keegan P; Pazdur R
Clin Cancer Res; 2017 May; 23(10):2377-2381. PubMed ID: 28073840
[TBL] [Abstract][Full Text] [Related]
23. Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma.
Sanmartín O; Llombart B; Carretero Hernández G; Flórez Menéndez Á; Botella-Estrada R; Herrera Ceballos E; Puig S
Actas Dermosifiliogr (Engl Ed); 2021 Apr; 112(4):295-301. PubMed ID: 33197438
[TBL] [Abstract][Full Text] [Related]
24. Clinical determinants of clinical response to Sonidegib in advanced basal cell carcinoma: a monocenter experience.
Spallone G; Carbone A; Sperati F; Frascione P; Eibenschutz L
Eur Rev Med Pharmacol Sci; 2024 Apr; 28(7):2923-2928. PubMed ID: 38639529
[TBL] [Abstract][Full Text] [Related]
25. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
Rodon J; Tawbi HA; Thomas AL; Stoller RG; Turtschi CP; Baselga J; Sarantopoulos J; Mahalingam D; Shou Y; Moles MA; Yang L; Granvil C; Hurh E; Rose KL; Amakye DD; Dummer R; Mita AC
Clin Cancer Res; 2014 Apr; 20(7):1900-9. PubMed ID: 24523439
[TBL] [Abstract][Full Text] [Related]
26. A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature.
Passarelli A; Galdo G; Aieta M; Fabrizio T; Villonio A; Conca R
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202689
[TBL] [Abstract][Full Text] [Related]
27. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor.
Skvara H; Kalthoff F; Meingassner JG; Wolff-Winiski B; Aschauer H; Kelleher JF; Wu X; Pan S; Mickel L; Schuster C; Stary G; Jalili A; David OJ; Emotte C; Antunes AM; Rose K; Decker J; Carlson I; Gardner H; Stuetz A; Bertolino AP; Stingl G; De Rie MA
J Invest Dermatol; 2011 Aug; 131(8):1735-44. PubMed ID: 21430703
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation.
Villani A; Scalvenzi M; Micali G; Lacarrubba F; Genco L; Ruggiero A; Fornaro L; Guerrasio G; Potestio L
Expert Opin Drug Saf; 2023; 22(7):525-531. PubMed ID: 37326221
[TBL] [Abstract][Full Text] [Related]
29. Locally advanced basal cell carcinoma: Real-life data with sonidegib.
Toffoli L; Conforti C; Zelin E; Vezzoni R; Agozzino M; di Meo N; Zalaudek I
Dermatol Ther; 2022 Jun; 35(6):e15441. PubMed ID: 35279921
[TBL] [Abstract][Full Text] [Related]
30. Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits.
Villani A; Cinelli E; Fabbrocini G; Lallas A; Scalvenzi M
Expert Opin Drug Saf; 2020 Dec; 19(12):1585-1594. PubMed ID: 33054455
[TBL] [Abstract][Full Text] [Related]
31. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis.
Xie P; Lefrançois P
J Am Acad Dermatol; 2018 Dec; 79(6):1089-1100.e17. PubMed ID: 30003981
[TBL] [Abstract][Full Text] [Related]
32. Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study.
Moreno-Arrones OM; Béa-Ardebol S; Mayo-Martinez F; Pérez-Pastor G; Torres-Navarro I; Bonfill-Ortí M; Deza G; Ruiz-Salas V; Masferrer E; Feal C; Turrión-Merino L; Toll A; Yébenes M; Galiano-Mejías S; Jaka A; Ferrandiz-Pulido C; Florez A; Hernández-Hernández N; Fernández-de-Misa R; Rios-Buceta L; Sanmartin O
Actas Dermosifiliogr; 2023; 114(7):T565-T571. PubMed ID: 37302483
[TBL] [Abstract][Full Text] [Related]
33. Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study.
Moreno-Arrones OM; Béa-Ardebol S; Mayo-Martinez F; Pérez-Pastor G; Torres-Navarro I; Bonfill-Ortí M; Deza G; Ruiz-Salas V; Masferrer E; Feal C; Turrión-Merino L; Toll A; Yébenes M; Galiano-Mejías S; Jaka A; Ferrandiz-Pulido C; Florez A; Hernández-Hernández N; Fernández-de-Misa R; Rios-Buceta L; Sanmartin O
Actas Dermosifiliogr; 2023; 114(7):565-571. PubMed ID: 37088285
[TBL] [Abstract][Full Text] [Related]
34. Sonidegib for the treatment of advanced basal cell carcinoma.
Ramelyte E; Amann VC; Dummer R
Expert Opin Pharmacother; 2016 Oct; 17(14):1963-8. PubMed ID: 27538055
[TBL] [Abstract][Full Text] [Related]
35. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
[TBL] [Abstract][Full Text] [Related]
36. Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review.
Patel S; Armbruster H; Pardo G; Archambeau B; Kim NH; Jeter J; Wu R; Kendra K; Contreras CM; Spaccarelli N; Dulmage B; Pootrakul L; Carr DR; Verschraegen C
PLoS One; 2024; 19(4):e0297531. PubMed ID: 38687774
[TBL] [Abstract][Full Text] [Related]
37. Sonidegib with and Without Adjunctive Treatment for Locally Advanced Basal Cell Carcinomas.
Villani A; Fabbrocini G; Costa C; Potestio L; Scalvenzi M
Oncologist; 2022 Jun; 27(6):e533. PubMed ID: 35436344
[No Abstract] [Full Text] [Related]
38. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
Danial C; Sarin KY; Oro AE; Chang AL
Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
[TBL] [Abstract][Full Text] [Related]
39. Noninvasive monitoring of basal cell carcinomas treated with systemic hedgehog inhibitors: pseudocysts as a sign of tumor regression.
Maier T; Kulichova D; Ruzicka T; Berking C
J Am Acad Dermatol; 2014 Oct; 71(4):725-30. PubMed ID: 24928708
[TBL] [Abstract][Full Text] [Related]
40. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.
Wahid M; Jawed A; Mandal RK; Dar SA; Khan S; Akhter N; Haque S
Crit Rev Oncol Hematol; 2016 Feb; 98():235-41. PubMed ID: 26614022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
